Education
About Us
Working with TipRanks
Follow Us
Vera Therapeutics, Inc. (VERA)
NASDAQ:VERA
VERA Stock Chart & Stats
$40.53
-$0.18(-0.43%)
At close: 4:00 PM EST
$40.53
-$0.18(-0.43%)
Day’s Range― - ―
52-Week Range$18.53 - $56.05
Previous CloseN/A
Volume142.65K
Average Volume (3M)1.17M
Market Cap
$2.89B
Enterprise Value$2.61B
Total Cash (Recent Filing)$714.59M
Total Debt (Recent Filing)$77.31M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
May 07, 2026EPS Estimate
-1.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding71,355,670
10 Day Avg. Volume1,517,543
30 Day Avg. Volume1,166,613
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)5.38
Price to Sales (P/S)0.00
P/FCF Ratio-13.46
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.11
Forecast
1Y Price Target
$83.50Price Target Upside106.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-5.21
Revenue Forecast (FY)$44.09M
Bulls Say, Bears Say
Bulls Say
Commercial Readiness And Market OpportunityAnalyst points to planned hiring of a focused US sales force combined with an expected broad label and a large addressable IgA nephropathy market, indicating significant commercial upside if approval is secured.
Phase 3 Clinical Efficacy And SafetyAnalyst highlights pivotal trial results showing substantial proteinuria reduction and high rates of hematuria resolution with no increase in serious adverse events versus placebo, supporting a compelling clinical profile.
Regulatory ProgressAnalyst notes FDA acceptance of the biologics license application with Priority Review, increasing the likelihood of an accelerated approval pathway for atacicept and supporting prospects for regulatory clearance.
Bears Say
Competitive Pressure From VertexAnalyst warns that Vertex's greater convenience in administration could capture market share and leave Vera at a competitive disadvantage for adoption of atacicept.
Funding And Cash Runway RiskAnalyst highlights high cash burn and a limited operating runway, creating potential funding risk and dependence on capital markets before meaningful product revenues emerge.
Tolerability ConcernsAnalyst notes more frequent injection site reactions observed with the treatment, which could reduce patient tolerability and slow prescribing uptake by clinicians.
Vera Therapeutics News
VERA FAQ
What was Vera Therapeutics, Inc.’s price range in the past 12 months?
Vera Therapeutics, Inc. lowest stock price was $18.53 and its highest was $56.05 in the past 12 months.
What is Vera Therapeutics, Inc.’s market cap?
Vera Therapeutics, Inc.’s market cap is $2.89B.
When is Vera Therapeutics, Inc.’s upcoming earnings report date?
Vera Therapeutics, Inc.’s upcoming earnings report date is May 07, 2026 which is in 44 days.
How were Vera Therapeutics, Inc.’s earnings last quarter?
Vera Therapeutics, Inc. released its earnings results on Feb 26, 2026. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.325 by -$0.065.
Is Vera Therapeutics, Inc. overvalued?
According to Wall Street analysts Vera Therapeutics, Inc.’s price is currently Undervalued.
Does Vera Therapeutics, Inc. pay dividends?
Vera Therapeutics, Inc. does not currently pay dividends.
What is Vera Therapeutics, Inc.’s EPS estimate?
Vera Therapeutics, Inc.’s EPS estimate is -1.33.
How many shares outstanding does Vera Therapeutics, Inc. have?
Vera Therapeutics, Inc. has 71,355,670 shares outstanding.
What happened to Vera Therapeutics, Inc.’s price movement after its last earnings report?
Vera Therapeutics, Inc. reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.325. Following the earnings report the stock price went up 1.607%.
Which hedge fund is a major shareholder of Vera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in VERA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vera Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$83.50 (106.02% Upside)
$83.50 (106.02% Upside)
Blogger Sentiment
Bullish
VERA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 640.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.31%
12-Months-Change
Fundamentals
Return on Equity
-59.72%
Trailing 12-Months
Asset Growth
12.01%
Trailing 12-Months
Company Description
Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
VERA Stock 12 Month Forecast
Average Price Target
$83.50
▲(106.02% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
12.99% Insiders
16.20% Mutual Funds
53.04% Other Institutional Investors
4.34% Public Companies and
Individual Investors